Antigen response enhancer
An antigen response enhancer using Euglena and β-1,3-glucan increases naive T cells and enhances immune markers to improve immune function and counteract aging-related immune decline.
JP2026105098APending Publication Date: 2026-06-25KOBELCO ECO SOLUTIONS CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- KOBELCO ECO SOLUTIONS CO LTD
- Filing Date
- 2026-04-23
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
As organisms age, the immune system declines due to an increase in senescent T cells and a decrease in naive T cells, leading to reduced antigen responsiveness, which compromises the immune defense mechanism.
Method used
An antigen response enhancer containing Euglena, paramylon, or β-1,3-glucan is developed to promote the increase in naive T cells, enhance CD28 expression, and increase other immune markers such as CD80, CD86, and HLA-DR in monocytes, thereby boosting the immune response.
Benefits of technology
The enhancer effectively increases the number and activity of naive T cells and regulatory T cells, enhances antigen presentation, and improves overall immune function, counteracting immunosenescence.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026105098000002 
Figure 2026105098000003 
Figure 2026105098000004
Abstract
To provide an antigen responsiveness enhancer. [Solution] From Euglena, paramylon, paramylon processed product, and β-1,3-glucan An antigen response enhancer containing at least one selected from the group.
Need to check novelty before this filing date? Find Prior Art